科华生物
(002022)
| 流通市值：29.42亿 | | | 总市值：29.42亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 837,514,899.5 | 395,096,525.16 | 1,642,485,860.08 | 1,191,260,566.76 |
| 营业总成本 | 926,878,905.69 | 437,618,477.31 | 2,015,713,933.66 | 1,395,129,544.97 |
| 其他经营收益 | | | | |
| 营业利润 | -90,575,131.27 | -41,792,380.14 | -808,227,334.24 | -250,732,621.08 |
| 利润总额 | -91,566,420.39 | -42,161,046.89 | -812,114,481.91 | -251,753,774.58 |
| 净利润 | -95,243,225.66 | -43,401,483.61 | -884,793,893.44 | -253,819,970.95 |
| 每股收益 | | | | |
| 其他综合收益 | -18,467,662.77 | -12,048,291.49 | 19,571,301.35 | 25,828,113.66 |
| 综合收益总额 | -113,710,888.43 | -55,449,775.1 | -865,222,592.09 | -227,991,857.29 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,299,546,182.78 | 2,337,116,089.49 | 2,407,157,950.45 | 2,716,522,275.75 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,174,448,885.48 | 2,209,611,955.96 | 2,234,277,271.4 | 2,453,684,802.06 |
| 资产总计 | 4,473,995,068.26 | 4,546,728,045.45 | 4,641,435,221.85 | 5,170,207,077.81 |
| 流动负债: | | | | |
| 流动负债合计 | 1,324,469,840.67 | 1,321,893,917.03 | 1,352,640,455.04 | 1,230,500,772.37 |
| 非流动负债: | | | | |
| 非流动负债合计 | 160,667,433.07 | 174,196,793.38 | 179,242,295.98 | 192,949,877.55 |
| 负债合计 | 1,485,137,273.74 | 1,496,090,710.41 | 1,531,882,751.02 | 1,423,450,649.92 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,516,352,850.19 | 2,577,979,876.95 | 2,637,914,841.01 | 3,143,739,195.84 |
| 股东权益合计 | 2,988,857,794.52 | 3,050,637,335.04 | 3,109,552,470.83 | 3,746,756,427.89 |
| 负债和股东权益合计 | 4,473,995,068.26 | 4,546,728,045.45 | 4,641,435,221.85 | 5,170,207,077.81 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 889,122,737.45 | 389,658,281.24 | 1,917,813,770.31 | 1,408,569,868.23 |
| 经营活动现金流出小计 | 943,571,912.19 | 492,021,339.01 | 1,895,375,104.93 | 1,432,666,849.58 |
| 经营活动产生的现金流量净额 | -54,449,174.74 | -102,363,057.77 | 22,438,665.38 | -24,096,981.35 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 66,884,224.74 | 63,629,672.3 | 11,638,264.31 | 7,309,152.33 |
| 投资活动现金流出小计 | 60,700,050.91 | 23,922,356.82 | 199,293,855.38 | 96,368,018.83 |
| 投资活动产生的现金流量净额 | 6,184,173.83 | 39,707,315.48 | -187,655,591.07 | -89,058,866.5 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 323,399,068.35 | 134,496,697.9 | 651,173,920.12 | 380,789,640.48 |
| 筹资活动现金流出小计 | 296,876,001.61 | 127,856,344.28 | 493,892,821.5 | 259,619,517.57 |
| 筹资活动产生的现金流量净额 | 26,523,066.74 | 6,640,353.62 | 157,281,098.62 | 121,170,122.91 |
| 汇率变动对现金及现金等价物的影响 | -6,342,369.79 | -1,320,334.43 | 732,215.21 | -606,958.05 |
| 现金及现金等价物净增加额 | -28,084,303.96 | -57,335,723.1 | -7,203,611.86 | 7,407,317.01 |
| 期末现金及现金等价物余额 | 825,089,342.1 | 795,837,922.96 | 853,173,646.06 | 867,784,574.93 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -28,084,303.96 | - | -7,203,611.86 | - |